Today announced that it provides received U Get more information.

AVERT System receives FDA clearance for controlled infusion of radiopaque comparison media in angiographic procedures Osprey Medical Inc Get more information . today announced that it provides received U.S. The AVERT System is normally a proprietary technology made to reduce the quantity of dye injected and subjected to individuals undergoing angiogram or diagnostic heart methods. In a pilot individual clinical study, the AVERT System was proven to reduce the quantity of dye by up to 40 percent without compromising image quality. There are approximately 4. 4 million angiogram and STEMI heart techniques performed in Western European countries and america annually. AVERT was not yet part of our plans when we undertook our IPO in-may 2012. Developing the Avert System and obtaining FDA clearance in such a short period of time is normally testament to the features of our team at Osprey and potentially opens up further thrilling opportunities for the business.

Independent radiology review will be conducted for all CT radiographs and scans. Patients with RCC of clear cell histology that have had a prior nephrectomy and that have not received prior VEGF-targeted therapy are eligible for this trial. Patients who demonstrate disease progression during treatment with sorafenib will have the opportunity to be treated with tivozanib by participating in a separate long-term treatment protocol. Additional information on the trial design can be found online at To launching TIVO-1 Prior, AVEO successfully completed a 272-patient Phase 2 clinical trial of tivozanib in patients with advanced RCC.